Kymera Therapeutics’ (KYMR) “Buy” Rating Reaffirmed at BTIG Research

Kymera Therapeutics (NASDAQ:KYMR)‘s stock had its “buy” rating reiterated by stock analysts at BTIG Research in a research report issued on Tuesday,Benzinga reports. They presently have a $138.00 price objective on the stock. BTIG Research’s target price indicates a potential upside of 82.49% from the company’s previous close.

Other equities analysts have also recently issued reports about the stock. Morgan Stanley lifted their target price on shares of Kymera Therapeutics from $73.00 to $127.00 and gave the company an “overweight” rating in a report on Tuesday, December 9th. Truist Financial lifted their price objective on shares of Kymera Therapeutics from $80.00 to $116.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. JPMorgan Chase & Co. upped their target price on shares of Kymera Therapeutics from $70.00 to $125.00 and gave the company an “overweight” rating in a report on Wednesday, December 10th. Citigroup raised their price target on Kymera Therapeutics from $80.00 to $110.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Finally, Barclays boosted their price target on Kymera Therapeutics to $133.00 and gave the company an “overweight” rating in a research report on Tuesday, January 27th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $117.00.

Kymera Therapeutics Price Performance

NASDAQ KYMR opened at $75.62 on Tuesday. The firm’s fifty day moving average price is $75.83 and its 200 day moving average price is $60.13. The company has a market capitalization of $5.44 billion, a price-to-earnings ratio of -21.06 and a beta of 2.21. Kymera Therapeutics has a 12 month low of $19.44 and a 12 month high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.19). The firm had revenue of $2.76 million for the quarter, compared to analysts’ expectations of $23.15 million. Kymera Therapeutics had a negative return on equity of 32.92% and a negative net margin of 674.81%. As a group, sell-side analysts forecast that Kymera Therapeutics will post -2.79 earnings per share for the current year.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, Director Bruce Booth sold 229,809 shares of the business’s stock in a transaction that occurred on Wednesday, December 10th. The stock was sold at an average price of $91.73, for a total transaction of $21,080,379.57. Following the transaction, the director owned 686,477 shares in the company, valued at approximately $62,970,535.21. The trade was a 25.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Bros. Advisors Lp Baker bought 2,005,813 shares of the business’s stock in a transaction dated Thursday, December 11th. The shares were acquired at an average cost of $86.00 per share, with a total value of $172,499,918.00. Following the completion of the purchase, the director owned 7,955,916 shares in the company, valued at approximately $684,208,776. This represents a 33.71% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders sold 420,895 shares of company stock valued at $37,778,351. Insiders own 16.01% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of KYMR. Farther Finance Advisors LLC lifted its holdings in Kymera Therapeutics by 642.9% in the second quarter. Farther Finance Advisors LLC now owns 624 shares of the company’s stock valued at $27,000 after acquiring an additional 540 shares during the period. PNC Financial Services Group Inc. increased its holdings in shares of Kymera Therapeutics by 506.6% in the 2nd quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock valued at $40,000 after purchasing an additional 770 shares in the last quarter. Larson Financial Group LLC lifted its stake in shares of Kymera Therapeutics by 81.5% in the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after purchasing an additional 349 shares during the period. Osaic Holdings Inc. boosted its holdings in Kymera Therapeutics by 18,050.0% during the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after buying an additional 1,083 shares in the last quarter. Finally, Bessemer Group Inc. boosted its holdings in Kymera Therapeutics by 652.0% during the third quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock worth $53,000 after buying an additional 815 shares in the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.